HU000031061T2

(19) **HU**

(11) Lajstromszám: **E 031 061**

(13) **T2**

MAGYARORSZÁG
Szellemi Tulajdon Nemzeti Hivatala

EURÓPAI SZABADALOM
SZÖVEGÉNEK FORDÍTÁSA

(21) Magyar ügyszám: **E 06 718129**
(22) A bejelentés napja: **2006. 01. 11.**

(96) Az európai bejelentés bejelentési száma:
EP 20060718129
(97) Az európai bejelentés közzétételi adatai:
EP 1845925 A2 **2006. 07. 20.**
(97) Az európai szabadalom megadásának meghirdetési adatai:
EP 1845925 B1 **2016. 08. 24.**

(51) Int. Cl.: ***A61J 1/20*** *(2006.01)*

(86) A nemzetközi (PCT) bejelentési szám:
PCT/US 06/001016
(87) A nemzetközi közzétételi szám:
WO 06076453

(30) Elsőbbségi adatok:
643273 P **2005. 01. 12.** **US**

(72) Feltaláló(k):
FAULKNER, Eric, Anthony, North Andover, MA 01845 (US)
DI BIASE, Mary, Diana, Wellesley, MA 02481 (US)

(73) Jogosult(ak):
Biogen MA Inc., Cambridge, MA 02142 (US)

(74) Képviselő:
KOVÁRI Szabadalmi és Védjegy Iroda Kft., Budapest

(54) **Az interferon-béta szállítására szolgáló módszer**

(19) Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) EP 1 845 925 B1

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention of the grant of the patent:
24.08.2016 Bulletin 2016/34

(21) Application number: **06718129.7**

(22) Date of filing: **11.01.2006**

(51) Int Cl.:
A61J 1/20 *(2006.01)*

(86) International application number:
PCT/US2006/001016

(87) International publication number:
WO 2006/076453 (20.07.2006 Gazette 2006/29)

(54) **METHOD FOR DELIVERING INTERFERON-BETA**

VERFAHREN ZUR VERABREICHUNG VON INTERFERON-BETA

METHODE DE DISTRIBUTION D'INTERFERON BETA

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

(30) Priority: **12.01.2005 US 643273 P**

(43) Date of publication of application:
24.10.2007 Bulletin 2007/43

(73) Proprietor: **Biogen MA Inc.**
Cambridge, MA 02142 (US)

(72) Inventors:
- **FAULKNER, Eric, Anthony**
  North Andover, MA 01845 (US)
- **DI BIASE, Mary, Diana**
  Wellesley, MA 02481 (US)

(74) Representative: **Adams, Harvey Vaughan John et al**
Mathys & Squire LLP
The Shard
32 London Bridge Street
London SE1 9SG (GB)

(56) References cited:
EP-A- 1 258 234
EP-B- 0 948 358
WO-A-2004/100979

EP 1 845 925 B1

Description

TECHNICAL FIELD OF THE INVENTION

[0001] This invention relates to storing Interferon-β.

BACKGROUND OF THE INVENTION

[0002] Interferons are single chain polypeptides secreted by most animal cells in response to a variety of inducers, including viruses, mitogens and polynucleotides. Interferons participate in regulation of cell function, and have antiviral, antiproliferative and immunomodulating properties. Native human interferons are classified into three major types: Interferon-α (leukocyte), Interferon-ß (fibroblast) and Interferon-γ (immune). Native Interferon-ß is produced primarily by diploid fibroblast cells and in lesser amounts by lymphoblastoid cells.

[0003] Interferon-β is a glycoprotein. Its genetic nucleic acid and amino acid sequences have been determined. (Houghton et. al., "The Complete Amino Acid Sequence of Human Fibroblast Interferon as Deduced Using Synthetic Oligodeoxyribonucleotide Primers of Reverse Transcriptase," Nucleic Acids Research, 8, pp. 2885-94 (1980); T. Taniguchi et al., "The Nucleotide Sequence of Human Fibroblast DNA," Gene, 10, pp. 11-15 (1980)). Recombinant Interferon-ß has been produced and characterized.

[0004] Interferon-ß exhibits various biological and immunological activities, such as antiviral, anti-tumor and anti-cancer. Interferon-ß-1a is approved for sale in the United States for the treatment of multiple sclerosis under the trade name of Avonex®.

SUMMARY OF THE INVENTION

[0005] In general, this disclosure relates to storing solutions of Interferon-β such that the concentration of an aggregating metal is less than 500 parts per billion in the stored solution. Aggregating metals include iron, copper, nickel, molybdenum and tungsten. Devices useful for storing Interferon-β include, but are not limited to, syringes, vials, bottles, bags and the like.

[0006] In one instance , the disclosure provides a method for storing and delivering solutions of Interferon-β including providing a device having a housing for retaining the solution and filling the solution of Interferon-β into the housing. After filling the solution, the housing releases a concentration of an aggregating metal into the solution of less than 500 parts per billion.

[0007] In another instance, the housing releases a total concentration of aggregating metals into the solution of less than 500 parts per billion, less than 250 parts per billion, less than about 100 parts per billion, less than about 75 parts per billion, less than about 50 parts per billion, or less than about than 25 parts per billion.

[0008] In still another instance, the disclosure features a method for storing and delivering solutions of Interferon-β including providing a device having a housing for retaining the solution and filling the solution of Interferon-β into the housing. After filling the solution, aggregation of Interferon-β caused by aggregating metals in the solution is less than 15% after storage, less than 10% after storage, less than 5% after storage, less than 2% after storage.

[0009] In yet another instance, the disclosure features a device for storing and delivering solutions of Interferon-β including a housing for retaining an Interferon-β solution and a solution of Interferon-β wherein the housing releases a total concentration of aggregating metals into the solution of less than 500 parts per billion, less than 250 parts per billion, less than about 100 parts per billion, less than about 75 parts per billion, less than about 50 parts per billion, or less than about than 25 parts per billion.

[0010] In one instance, aggregation of Interferon-β caused by aggregating metals in the solution of Interferon-β contained in the housing is less than 15% after storage, less than 10% after storage, less than 5% after storage, less than 2% after storage.

[0011] Instances of the disclosure include one or more of the following. The housing releases a concentration of an aggregating metal or total concentration of aggregating metals of less than 500 parts per billion after the solution is retained in the housing for greater than about 10 minutes, greater than about 120 minutes, greater than about 360 minutes, greater than about 480 minutes. The housing releases a concentration of an aggregating metal or total concentration of aggregating metals of less than about 500 parts per billion after the solution is retained in the housing between about 120 minutes to about 480 minutes or between about 300 minutes to about 420 minutes. The housing releases a concentration of an aggregating metal or total concentration of aggregating metals of less than about 250 parts per billion, less than about 100 parts per billion, less than about 75 parts per billion, less than about 50 parts per billion, less than about than 25 parts per billion. The aggregating metal is iron, copper, nickel, molybdenum or tungsten. The device is a syringe, bottle, vial or a bag. The housing of the device is constructed of glass, metal or plastic. The Interferon-β is Interferon-β-1a.

[0012] Based on the disclosure that is contained herein, the present invention provides a method for producing a device that includes a housing for retaining a solution of Interferon-β, wherein the method comprises:

(a) cleaning the housing with acid and basic washes so as to remove or reduce the amount of aggregating metal on the surface that, in use, would be in direct contact with the solution of Interferon-β;
(b) filling the solution of Interferon-β into the housing, wherein, after filling the solution, the housing releases a concentration of aggregating metal into the solution of less than 500 parts per billion after the solution is retained in the housing for greater than about 10 minutes.

[0013] In a related aspect, the present invention provides a method for producing a device that includes a housing for retaining a solution of Interferon-β, wherein the method comprises:

(a) constructing the housing so as to reduce the amount of aggregating metal on the surface that, in use, would be in direct contact with the solution of Interferon-β;
(b) filling the solution of Interferon-β into the housing, wherein, after filling the solution, the housing releases a concentration of aggregating metal into the solution of less than 500 parts per billion after the solution is retained in the housing for greater than about 10 minutes.

[0014] In a further aspect, the invention provides a device comprising:

(a) a housing for retaining a solution of Interferon-β;
(b) a solution of Interferon-β retained within the housing,

wherein the housing releases a concentration of aggregating metal into the Interferon-β solution of less than 500 parts per billion after the solution is retained in the housing for greater than about 10 minutes.

[0015] The present invention and embodiments thereof are set out in the appended claims.

BRIEF DESCRIPTION OF THE DRAWINGS

[0016]

Figure 1 is a plot of the percent aggregation of Interferon-ß-1a as a function of time and the concentration of an aggregating metal, tungsten, after four weeks of storage in a commercially available syringe containing aggregating metals at 25°C at 60% relative humidity.
Figure 2 illustrates a device for storing Interferon-B.
Figure 3 is an end-on view of the device shown in Fig. 2 taken along the segment A.
Figure 4 illustrates alternative devices useful for storing Interferon-B.

DETAILED DESCRIPTION OF THE INVENTION

Definitions

[0017] As used herein, the term "Interferon-ß" refers to all forms of interferon-ß such as interferon-ß-1a.

[0018] As used herein, the term "aggregation" refers to increased interaction between Interferon molecules to cause increased opalescence, particulate formation or precipitation of the Interferon-ß from solution.

[0019] As used herein, the term "aggregating metals in an amount less than a certain number of parts per billion" refers to the amount of aggregating metals which are carried from the housing of a device into a wash solution of Avonex® liquid formulation, in which the wash solution is placed in contact with the device housing for about 240 minutes to about 480 minutes, for about 300 minutes to about 420 minutes, or from about 345 minutes to about 375 minutes.

[0020] As used herein, the term "less than a certain number of parts per billion of tungsten" refers to the amount of aggregating metals which are carried from the housing of a device into a wash solution of Avonex® liquid formulation, in which the wash solution is applied to the device housing for about 240 minutes to about 480 minutes, for about 300 minutes to about 420 minutes, or from about 345 minutes to about 375 minutes.

[0021] As used herein, the term "device" refers to any means for storing or delivering Interferon-B.

[0022] As used herein, the term housing" refers to an element of a device that is in direct contact with Interferon-ß for more than about 10 minutes.

[0023] As used herein, the term "wash solution" refers to the solution, such as a placebo formulation, used to determine the amount of an aggregating metal released from the device into the solution.

[0024] As used herein, the term "placebo formulation" refers to the solution including the components of a drug composition without the drug.

[0025] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In addition, the materials, methods and examples are illustrative only and not intended to be limiting.

[0026] Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.

Description of the Invention

[0027] In general, the disclosure relates to a method for storing and delivering solutions of Interferon-ß such that the concentration of aggregating metal (each metal individually or total of all aggregating metals) is less than 500 parts per billion in the solution after storage, e.g., after storage greater than 10 minutes, 120 minutes, 360 minutes, or 480 minutes. Certain metals cause aggregation of Interferon-ß. For example, as shown in Figure 1, an increasing concentration of the aggregating metal, such as tungsten, increases the degree of aggregation of interferon-ß-1a.

[0028] Aggregation is undesirable because it causes opalescence, particulate formation and precipitation of the drug. Further, aggregation can lead to a lower bioavailability of the drug and difficulty in delivering the Interferon-ß. The method described herein reduces the amount of aggregating metals released into a stored solution of Interferon-ß to provide less than about 15%, 10%, 5%, or 2% aggregation as measured by size ex-

clusion chromatography.

[0029] The invention provides a device for retaining a solution of Interferon-β so that the concentration of aggregating metals (each metal individually or the total of all aggregating metals) is less than 500 parts per billion in the solution after the solution is retained in the device for greater than 10 minutes, 120 minutes, 360 minutes, or 480 minutes. In addition, the device described herein, reduces the amount of aggregating metals released into an Interferon-β solution retained within the housing to provide less than about 15%, 10%, 5%, or 2% aggregation.

[0030] Referring to Figures 2 and 3, a glass syringe 10 for delivering Interferon-ß includes a housing 20 for holding Interferon-ß-1a and a needle 30 for dispensing Interferon-ß-1a from housing 20 (Figure 2). The housing 20 includes a cylindrical wall 22 defining a central bore 24 (Figure 3). One end 26 of the housing connects to needle 30 and the other end 28 of the housing receives a plunger 32. Plunger 32 is disposed in central bore 24 to engage frictionally cylindrical wall 22. During delivery, plunger 32 is depressed to dispense Interferon-ß. During storage in syringe 10, an Interferon-ß solution is disposed in central bore 24 of housing 20 and is in physical contact with the end of plunger 32.

[0031] Syringe 10 is constructed or cleaned prior to use to remove or reduce the amount of aggregating metals on the surfaces of the syringe which would contact a solution of Interferon-ß. Generally, syringe 10 is constructed or cleaned prior to use to remove or reduce the amount of aggregating metals, such as iron, copper, nickel, molybdenum or tungsten, released from the surfaces of the syringe that would be in contact with the Interferon-ß solution during storage, e.g., greater than about 10, 120, 360, or 480 minutes, about 100, 200, 400, 700 or 1000 hours, between about 120 minutes to about 480 minutes, or between about 300 minutes to about 420 minutes of storage at temperatures between 2°C and 30°C.

[0032] Syringe 10 is constructed or cleaned such that less than 500, 250, 100, 75, 50 or 25 parts per billion of aggregating metals (individually or in total) are released from the syringe into a solution of Interferon-ß after storage. The construction or cleaning of the syringe also provides less than 15%, 10%, 5% or 2% aggregation in an Interferon-ß solution after storage of the solution in the syringe. The amount of aggregating metal released into a solution of Interferon-ß or placebo formulation may be measured by performing Inductively Coupled Plasma Mass Spectrometry or Atomic Absorption Spectroscopy on Interferon-ß solutions or placebo formulations.

[0033] Suitable syringe storage devices capable of providing storage conditions which reduce the percent aggregation and amount of aggregating metal to levels described above are available from Becton Dickinson and Bunder Glas GmbH. Other syringe storage devices are known in the art. For example, see U.S. Patent Nos. 6,352,522; 6,263,641; 4,895,716 and 4,266,557. These devices may be washed with concentrated sulfuric acid, e.g., 98%, to remove aggregating metals followed by one or more basic washes to neutralize any residual sulfuric acid before filling the device with Interferon-ß. After washing the device with the acid and basic solutions, the amount of aggregating metal remaining in the syringe may be determined by rinsing the syringe and performing Inductively Coupled Plasma Mass Spectrometry or Atomic Absorption Spectroscopy on a placebo formulation that was stored in the syringe for more than about 10 minutes.

[0034] Although the storage device is described above as a syringe, other devices for storing or delivering Interferon-ß are within the scope of the invention provided that the elements of each device that are in contact with the Interferon-ß for more than about 10 minutes release less than 500 parts per billion of aggregating metals into the solution of Interferon-ß. Each of these devices can be manufactured to reduce the amount of aggregating metals that may release into the stored solutions or the device can be cleaned with acid and basic washes. Examples of other storage devices include ampoules (40, Fig. 4), vials (45, Fig 4) and bags (50, Fig. 4).

[0035] The invention will be further described in the following examples, which do not limit the scope of the invention described in the claims.

EXAMPLES

Example 1 - General Procedure for Determination of Aggregating Metal Release:

[0036] The following procedure can be used to determine the amount of aggregating metals released into a solution after storage.

[0037] A random selection of containers in which Interferon-ß is to be stored is selected from a manufacturing lot. Each container in the random selection is filled with a placebo formulation including all of the components of the formulation except Interferon-ß. The filled containers are stored at ambient temperature for a period of about greater than 360 minutes. The placebo formulations are analyzed by any suitable means to determine the concentration of aggregating metals. Suitable analytical methods include, but are not limited to, Inductively Coupled Mass Spectrometry and Atomic Absorption Spectroscopy.

Example 2 - Determination of Aggregating Metal Release from Avonex®:

[0038] Avonex® liquid formulation contains Interferon-ß-1a, sodium acetate trihydrate, glacial acetic acid, arginine hydrochloride and polysorbate-20 in Water For Injection (WFI). Specifically, each 0.5 mL (30 mcg dose) of Avonex® in a prefilled glass syringe contains 30 mcg of Interferon-β-1a, 0.79 mg sodium acetate trihydrate, 0.25 mg glacial acetic acid, 15.8 mg arginine hydrochlo-

ride and 0.025 mg polysorbate-20 in WFI at a pH of approximately 4.8. The placebo formulation is prepared by combining each of the components of the Avonex® formulation minus the Interferon-β-1a. Examples of formulations of Interferon-β are described in International Publication No. WO 98/28007 the entire contents of which are incorporated herein by reference. A random sample of syringes, such as 60, from a manufacturing lot is selected to evaluate the amount of aggregating metals released into stored solutions. The syringes are filled with the placebo formulation and stored for a period of between 360 to 480 minutes, optionally with sonication for about 5 minutes at room temperature. A sample of the placebo formulation is analyzed by Inductively Coupled Mass Spectrometry to determine the amount of aggregating metals.

Claims

1. A method for producing a device that includes a housing for retaining a solution of Interferon-β, wherein the method comprises:

   (a) cleaning the housing with acid and basic washes so as to remove or reduce the amount of aggregating metal on the surface that, in use, would be in direct contact with the solution of Interferon-β;
   (b) filling the solution of Interferon-β into the housing, wherein, after filling the solution, the housing releases a concentration of aggregating metal into the solution of less than 500 parts per billion after the solution is retained in the housing for greater than about 10 minutes.

2. A method for producing a device that includes a housing for retaining a solution of Interferon-β, wherein the method comprises:

   (a) constructing the housing so as to reduce the amount of aggregating metal on the surface that, in use, would be in direct contact with the solution of Interferons-β;
   (b) filling the solution of Interferon-β into the housing, wherein, after filling the solution, the housing releases a concentration of aggregating metal into the solution of less than 500 parts per billion after the solution is retained in the housing for greater than about 10 minutes.

3. The method of Claim 1 or Claim 2, wherein the housing releases a concentration of aggregating metal of less than about 500 parts per billion after the solution is retained in the housing for greater than about 120 minutes.

4. The method of Claim 1 or Claim 2, wherein the housing releases a concentration of aggregating metal of less than about 500 parts per billion after the solution is retained in the housing for greater than about 360 minutes.

5. The method of Claim 1 or Claim 2, wherein the housing releases a concentration of aggregating metal of less than about 500 parts per billion after the solution is retained in the housing for greater than about 480 minutes.

6. The method of Claim 1 or Claim 2, wherein the housing releases a concentration of aggregating metal of less than about 500 parts per billion after the solution is retained in the housing for about 120 minutes to about 480 minutes.

7. The method of Claim 1 or Claim 2, wherein the housing releases a concentration of aggregating metal of less than about 500 parts per billion after the solution is retained in the housing for about 300 minutes to about 420 minutes.

8. The method of Claim 1 or Claim 2, wherein the housing releases a concentration of aggregating metal of less than about 250 parts per billion.

9. The method of Claim 1 or Claim 2, wherein the housing releases a concentration of aggregating metal of less than about 100 parts per billion.

10. The method of Claim 1 or Claim 2, wherein the housing releases a concentration of aggregating metal of less than about 75 parts per billion.

11. The method of Claim 1 or Claim 2, wherein the housing releases a concentration of aggregating metal of less than about 50 parts per billion.

12. The method of Claim 1 or Claim 2, wherein aggregation of Interferon-β caused by aggregating metal in the solution is less than 15% after storage.

13. The method of Claim 1 or Claim 2, wherein aggregation of Interferon-β caused by aggregating metal in the solution is less than 10% after storage.

14. The method of Claim 1 or Claim 2, wherein aggregation of Interferon-β caused by aggregating metal in the solution is less than 5% after storage.

15. The method Claim 1 or Claim 2, wherein aggregation of Interferon-β caused by aggregating metal in the solution is less than 2% after storage.

16. A device comprising:

   (a) a housing for retaining a solution of Interfer-

on-β;
(b) a solution of Interferon-β retained within the housing,

wherein the housing releases a concentration of aggregating metal into the Interferon-β solution of less than 500 parts per billion after the solution is retained in the housing for greater than about 10 minutes.

17. The device of Claim 16, wherein the housing releases a total concentration of aggregating metal of less than about 250 parts per billion.

18. The device of Claim 16, wherein the housing releases a total concentration of aggregating metal of less than about 100 parts per billion.

19. The device of Claim 16, wherein the housing releases a total concentration of aggregating metal of less than about 75 parts per billion.

20. The device of Claim 16, wherein the housing releases a total concentration of aggregating metal of less than about 50 parts per billion.

21. The device of Claim 16, wherein the housing releases a total concentration of aggregating metal of less than about 500 parts per billion after the solution is retained in the housing for greater than about 120 minutes.

22. The device of Claim 16, wherein the housing releases a total concentration of aggregating metal of less than about 500 parts per billion after the solution is retained in the housing for greater than about 360 minutes.

23. The device of Claim 16, wherein the housing releases a total concentration of aggregating metal of less than about 500 parts per billion after the solution is retained in the housing for greater than about 480 minutes.

24. The device of Claim 16, wherein the housing releases a total concentration of aggregating metal of less than about 500 parts per billion after the solution is retained in the housing for about 120 minutes to about 480 minutes.

25. The device of Claim 16, wherein the housing releases a total concentration of aggregating metal of less than about 500 parts per billion after the solution is retained in the housing for about 300 minutes to about 420 minutes.

26. The device of Claim 16, wherein the aggregation of Interferon-β caused by aggregating metal in the solution is less than 15% after storage.

27. The device of Claim 16, wherein the aggregation of Interferon-β caused by aggregating metal in the solution is less than 10% after storage.

28. The device of Claim 16, wherein the aggregation of Interferon-β caused by aggregating metal in the solution is less than 5% after storage.

29. The device of Claim 16, wherein the aggregation of Interferon-β caused by aggregating metal in the solution is less than 2% after storage.

30. The method of any one of Claims 1-15, or the device of any one of Claims 16-29, wherein the aggregating metal is selected from the group comprising iron, copper, nickel, molybdenum and tungsten.

31. The method or device of Claim 30, wherein the aggregating metal is tungsten.

32. The method of any one of Claims 1-15, or the device of any one of Claims 16-29, wherein the device is a syringe, bottle, vial or a bag.

33. The method or device of Claim 32, wherein the device is a syringe.

34. The method of any one of Claims 1-15, or the device of any one of Claims 16-29, wherein the housing of the device is constructed of glass, metal or plastic.

35. The method of Claim 34, wherein the housing is constructed of glass.

36. The method of any one of Claims 1-15 or 30-35, or the device of any one of Claims 15-35, wherein the Interferon-β is Interferon-β-1a.

Patentansprüche

1. Verfahren zum Produzieren einer Vorrichtung, welche ein Gehäuse zum Aufbewahren einer Interferon-β-Lösung enthält, wobei das Verfahren umfasst:

a) Reinigen des Gehäuses mit sauren und basischen Spülungen, sodass die Menge an aggregierendem Metall auf der Oberfläche, die bei Verwendung in direktem Kontakt mit der Interferon-β-Lösung wäre, entfernt oder reduziert wird;
b) Einfüllen der Interferon-β-Lösung in das Gehäuse, wobei das Gehäuse nach dem Einfüllen der Lösung eine Konzentration von aggregierendem Metall von unter 500 parts per billion in die Lösung abgibt, nachdem die Lösung für über etwa 10 Minuten in dem Gehäuse aufbewahrt ist.

2. Verfahren zum Produzieren einer Vorrichtung, welche ein Gehäuse zum Aufbewahren einer Interferon-β-Lösung enthält, wobei das Verfahren umfasst:

   a) Konstruieren des Gehäuses, sodass die Menge an aggregierendem Metall auf der Oberfläche, die bei Verwendung in direktem Kontakt mit der Interferon-β-Lösung wäre, reduziert wird;
   b) Einfüllen der Interferon-β-Lösung in das Gehäuse, wobei das Gehäuse nach dem Einfüllen der Lösung eine Konzentration von aggregierendem Metall von unter 500 parts per billion in die Lösung abgibt, nachdem die Lösung für über etwa 10 Minuten in dem Gehäuse aufbewahrt ist.

3. Verfahren nach Anspruch 1 oder Anspruch 2, wobei das Gehäuse eine Konzentration von aggregierendem Metall von unter etwa 500 parts per billion abgibt, nachdem die Lösung für über etwa 120 Minuten in dem Gehäuse aufbewahrt ist.

4. Verfahren nach Anspruch 1 oder Anspruch 2, wobei das Gehäuse eine Konzentration von aggregierendem Metall von unter etwa 500 parts per billion abgibt, nachdem die Lösung für über etwa 360 Minuten in dem Gehäuse aufbewahrt ist.

5. Verfahren nach Anspruch 1 oder Anspruch 2, wobei das Gehäuse eine Konzentration von aggregierendem Metall von unter etwa 500 parts per billion abgibt, nachdem die Lösung für über etwa 480 Minuten in dem Gehäuse aufbewahrt ist.

6. Verfahren nach Anspruch 1 oder Anspruch 2, wobei das Gehäuse eine Konzentration von aggregierendem Metall von unter etwa 500 parts per billion abgibt, nachdem die Lösung für etwa 120 Minuten bis etwa 480 Minuten in dem Gehäuse aufbewahrt ist.

7. Verfahren nach Anspruch 1 oder Anspruch 2, wobei das Gehäuse eine Konzentration von aggregierendem Metall von unter etwa 500 parts per billion abgibt, nachdem die Lösung für etwa 300 Minuten bis etwa 420 Minuten in dem Gehäuse aufbewahrt ist.

8. Verfahren nach Anspruch 1 oder Anspruch 2, wobei das Gehäuse eine Konzentration von aggregierendem Metall von unter etwa 250 parts per billion abgibt.

9. Verfahren nach Anspruch 1 oder Anspruch 2, wobei das Gehäuse eine Konzentration von aggregierendem Metall von unter etwa 100 parts per billion abgibt.

10. Verfahren nach Anspruch 1 oder Anspruch 2, wobei das Gehäuse eine Konzentration von aggregierendem Metall von unter etwa 75 parts per billion abgibt.

11. Verfahren nach Anspruch 1 oder Anspruch 2, wobei das Gehäuse eine Konzentration von aggregierendem Metall von unter etwa 50 parts per billion abgibt.

12. Verfahren nach Anspruch 1 oder Anspruch 2, wobei die Aggregation von Interferon-β, welche durch das aggregierende Metall in der Lösung verursacht wurde, nach Lagerung unter 15 % beträgt.

13. Verfahren nach Anspruch 1 oder Anspruch 2, wobei die Aggregation von Interferon-β, welche durch das aggregierende Metall in der Lösung verursacht wurde, nach Lagerung unter 10 % beträgt.

14. Verfahren nach Anspruch 1 oder Anspruch 2, wobei die Aggregation von Interferon-β, welche durch das aggregierende Metall in der Lösung verursacht wurde, nach Lagerung unter 5 % beträgt.

15. Verfahren nach Anspruch 1 oder Anspruch 2, wobei die Aggregation von Interferon-β, welche durch das aggregierende Metall in der Lösung verursacht wurde, nach Lagerung unter 2 % beträgt.

16. Vorrichtung, umfassend:

   a) ein Gehäuse zum Aufbewahren einer Interferon-β-Lösung;
   b) eine in dem Gehäuse aufbewahrte Interferon-β-Lösung,

   wobei das Gehäuse eine Konzentration von aggregierendem Metall von unter 500 parts per billion in die Interferon-β-Lösung abgibt, nachdem die Lösung für über etwa 10 Minuten in dem Gehäuse aufbewahrt ist.

17. Vorrichtung nach Anspruch 16, wobei das Gehäuse eine Gesamtkonzentration von aggregierendem Metall von unter etwa 250 parts per billion abgibt.

18. Vorrichtung nach Anspruch 16, wobei das Gehäuse eine Gesamtkonzentration von aggregierendem Metall von unter etwa 100 parts per billion abgibt.

19. Vorrichtung nach Anspruch 16, wobei das Gehäuse eine Gesamtkonzentration von aggregierendem Metall von unter etwa 75 parts per billion abgibt.

20. Vorrichtung nach Anspruch 16, wobei das Gehäuse eine Gesamtkonzentration von aggregierendem Metall von unter etwa 50 parts per billion abgibt.

21. Vorrichtung nach Anspruch 16, wobei das Gehäuse eine Gesamtkonzentration von aggregierendem Metall von unter etwa 500 parts per billion abgibt,

nachdem die Lösung für über etwa 120 Minuten in dem Gehäuse aufbewahrt ist.

22. Vorrichtung nach Anspruch 16, wobei das Gehäuse eine Gesamtkonzentration von aggregierendem Metall von unter etwa 500 parts per billion abgibt, nachdem die Lösung für über etwa 360 Minuten in dem Gehäuse aufbewahrt ist.

23. Vorrichtung nach Anspruch 16, wobei das Gehäuse eine Gesamtkonzentration von aggregierendem Metall von unter etwa 500 parts per billion abgibt, nachdem die Lösung für über etwa 480 Minuten in dem Gehäuse aufbewahrt ist.

24. Vorrichtung nach Anspruch 16, wobei das Gehäuse eine Gesamtkonzentration von aggregierendem Metall von unter etwa 500 parts per billion abgibt, nachdem die Lösung für etwa 120 Minuten bis etwa 480 Minuten in dem Gehäuse aufbewahrt ist.

25. Vorrichtung nach Anspruch 16, wobei das Gehäuse eine Gesamtkonzentration von aggregierendem Metall von unter etwa 500 parts per billion abgibt, nachdem die Lösung für etwa 300 Minuten bis etwa 420 Minuten in dem Gehäuse aufbewahrt ist.

26. Vorrichtung nach Anspruch 16, wobei die Aggregation von Interferon-β, welche durch das aggregierende Metall in der Lösung verursacht wurde, nach Lagerung unter 15 % beträgt.

27. Vorrichtung nach Anspruch 16, wobei die Aggregation von Interferon-β, welche durch das aggregierende Metall in der Lösung verursacht wurde, nach Lagerung unter 10 % beträgt.

28. Vorrichtung nach Anspruch 16, wobei die Aggregation von Interferon-β, welche durch das aggregierende Metall in der Lösung verursacht wurde, nach Lagerung unter 5 % beträgt.

29. Vorrichtung nach Anspruch 16, wobei die Aggregation von Interferon-β, welche durch das aggregierende Metall in der Lösung verursacht wurde, nach Lagerung unter 2 % beträgt.

30. Verfahren nach einem der Ansprüche 1-15 oder Vorrichtung nach einem der Ansprüche 16-29, wobei das aggregierende Metall aus der aus Eisen, Kupfer, Nickel, Molybdän oder Wolfram bestehenden Gruppe ausgewählt ist.

31. Verfahren oder Vorrichtung nach Anspruch 30, wobei das aggregierende Metall Wolfram ist.

32. Verfahren nach einem der Ansprüche 1-15 oder Vorrichtung nach einem der Ansprüche 16-29, wobei die Vorrichtung eine Spritze, Flasche, Ampulle oder ein Beutel ist.

33. Verfahren oder Vorrichtung nach Anspruch 32, wobei die Vorrichtung eine Spritze ist.

34. Verfahren nach einem der Ansprüche 1-15 oder Vorrichtung nach einem der Ansprüche 16-29, wobei das Gehäuse der Vorrichtung aus Glas, Metall oder Kunststoff gestaltet ist.

35. Verfahren nach Anspruch 34, wobei das Gehäuse aus Glas gestaltet ist.

36. Verfahren nach einem der Ansprüche 1-15 oder 30-35 oder Vorrichtung nach einem der Ansprüche 15-35, wobei das Interferon-β Interferon-β-1a ist.

Revendications

1. Procédé de fabrication d'un dispositif qui comprend un boîtier destiné à retenir une solution d'interféron β, dans lequel le procédé comprend :

(a) le nettoyage du boîtier avec des solutions acides et basiques de manière à éliminer ou réduire la quantité d'agrégation de métal sur la surface qui, en utilisation, serait en contact direct avec la solution d'interféron β ;
(b) le remplissage de la solution d'interféron β dans le boîtier, dans lequel, après le remplissage de la solution, le boîtier libère une concentration d'agrégation de métal dans la solution de moins de 500 parties par milliard après que la solution est retenue dans le boîtier pendant plus d'environ 10 minutes.

2. Procédé de fabrication d'un dispositif qui comprend un boîtier destiné à retenir une solution d'interféron β, dans lequel le procédé comprend :

(a) la construction du boîtier de manière à réduire la quantité d'agrégation de métal sur la surface qui, en utilisation, serait en contact direct avec la solution d'interféron β ;
(b) le remplissage de la solution d'interféron β dans le boîtier, dans lequel, après remplissage de la solution, le boîtier libère une concentration d'agrégation de métal dans la solution de moins de 500 parties par milliard après que la solution est retenue dans le boîtier pendant plus d'environ 10 minutes.

3. Procédé selon la revendication 1 ou la revendication 2, dans lequel le boîtier libère une concentration d'agrégation de métal inférieure à environ 500 parties par milliard après que la solution est retenue

dans le boîtier pendant plus d'environ 120 minutes.

4. Procédé selon la revendication 1 ou la revendication 2, dans lequel le boîtier libère une concentration d'agrégation de métal inférieure à environ 500 parties par milliard après que la solution est retenue dans le boîtier pendant plus d'environ 360 minutes.

5. Procédé selon la revendication 1 ou la revendication 2, dans lequel le boîtier libère une concentration d'agrégation de métal inférieure à environ 500 parties par milliard après que la solution est retenue dans le boîtier pendant plus d'environ 480 minutes.

6. Procédé selon la revendication 1 ou la revendication 2, dans lequel le boîtier libère une concentration d'agrégation de métal inférieure à environ 500 parties par milliard après que la solution est retenue dans le boîtier pendant environ 120 minutes à environ 480 minutes.

7. Procédé selon la revendication 1 ou la revendication 2, dans lequel le boîtier libère une concentration d'agrégation de métal inférieure à environ 500 parties par milliard après que la solution est retenue dans le boîtier pendant environ 300 minutes à environ 420 minutes.

8. Procédé selon la revendication 1 ou la revendication 2, dans lequel le boîtier libère une concentration d'agrégation de métal inférieure à environ 250 parties par milliard.

9. Procédé selon la revendication 1 ou la revendication 2, dans lequel le boîtier libère une concentration d'agrégation de métal inférieure à environ 100 parties par milliard.

10. Procédé selon la revendication 1 ou la revendication 2, dans lequel le boîtier libère une concentration d'agrégation de métal inférieure à environ 75 parties par milliard.

11. Procédé selon la revendication 1 ou la revendication 2, dans lequel le boîtier libère une concentration d'agrégation de métal inférieure à environ 50 parties par milliard.

12. Procédé selon la revendication 1 ou la revendication 2, dans lequel l'agrégation d'interféron β provoquée par l'agrégation de métal dans la solution est inférieure à 15 % après stockage.

13. Procédé selon la revendication 1 ou la revendication 2, dans lequel l'agrégation d'interféron β provoquée par l'agrégation de métal dans la solution est inférieure à 10 % après stockage.

14. Procédé selon la revendication 1 ou la revendication 2, dans lequel l'agrégation d'interféron β provoquée par l'agrégation de métal dans la solution est inférieure à 5 % après stockage.

15. Procédé selon la revendication 1 ou de la revendication 2, dans lequel l'agrégation d'interféron β provoquée par l'agrégation de métal dans la solution est inférieure à 2 % après stockage.

16. Dispositif comprenant :

(a) un boîtier destiné à retenir une solution d'interféron β ;
(b) une solution d'interféron β retenue à l'intérieur du boîtier,

dans lequel le boîtier libère une concentration d'agrégation de métal dans la solution d'interféron β de moins de 500 parties par milliard après que la solution est retenue dans le boîtier pendant plus de 10 minutes environ.

17. Dispositif selon la revendication 16, dans lequel le boîtier libère une concentration totale d'agrégation de métal inférieure à environ 250 parties par milliard.

18. Dispositif selon la revendication 16, dans lequel le boîtier libère une concentration totale d'agrégation de métal inférieure à environ 100 parties par milliard.

19. Dispositif selon la revendication 16, dans lequel le boîtier libère une concentration totale d'agrégation de métal inférieure à environ 75 parties par milliard.

20. Dispositif selon la revendication 16, dans lequel le boîtier libère une concentration totale d'agrégation de métal inférieure à environ 50 parties par milliard.

21. Dispositif selon la revendication 16, dans lequel le boîtier libère une concentration totale d'agrégation de métal inférieure à environ 500 parties par milliard après que la solution est retenue dans le boîtier pendant plus de 120 minutes environ.

22. Dispositif selon la revendication 16, dans lequel le boîtier libère une concentration totale d'agrégation de métal inférieure à environ 500 parties par milliard après que la solution est retenue dans le boîtier pendant plus de 360 minutes environ.

23. Dispositif selon la revendication 16, dans lequel le boîtier libère une concentration totale d'agrégation de métal inférieure à environ 500 parties par milliard après que la solution est retenue dans le boîtier pendant plus de 480 minutes environ.

24. Dispositif selon la revendication 16, dans lequel le

boîtier libère une concentration totale d'agrégation de métal inférieure à environ 500 parties par milliard après que la solution est retenue dans le boîtier pendant environ 120 minutes à environ 480 minutes.

25. Dispositif selon la revendication 16, dans lequel le boîtier libère une concentration totale d'agrégation de métal inférieure à environ 500 parties par milliard après que la solution est retenue dans le boîtier pendant environ 300 minutes à environ 420 minutes.

26. Dispositif selon la revendication 16, dans lequel l'agrégation d'interféron β provoquée par l'agrégation de métal dans la solution est inférieure à 15 % après stockage.

27. Dispositif selon la revendication 16, dans lequel l'agrégation d'interféron β provoquée par l'agrégation de métal dans la solution est inférieure à 10 % après stockage.

28. Dispositif selon la revendication 16, dans lequel l'agrégation d'interféron β provoquée par l'agrégation de métal dans la solution est inférieure à 5 % après stockage.

29. Dispositif selon la revendication 16, dans lequel l'agrégation d'interféron β provoquée par l'agrégation de métal dans la solution est inférieure à 2 % après stockage.

30. Procédé selon l'une quelconque des revendications 1 à 15, ou dispositif selon l'une quelconque des revendications 16 à 29, dans lequel l'agrégation de métal est choisie dans le groupe comprenant le fer, le cuivre, le nickel, le molybdène et le tungstène.

31. Procédé ou dispositif selon la revendication 30, dans lequel l'agrégation de métal est du tungstène.

32. Procédé selon l'une quelconque des revendications 1 à 15, ou dispositif selon l'une quelconque des revendications 16 à 29, dans lequel le dispositif est une seringue, une bouteille, un flacon ou une poche.

33. Procédé ou dispositif selon la revendication 32, dans lequel le dispositif est une seringue.

34. Procédé selon l'une quelconque des revendications 1 à 15, ou dispositif selon l'une quelconque des revendications 16 à 29, dans lequel le boîtier du dispositif est construit en verre, en métal ou en plastique.

35. Procédé selon la revendication 34, dans lequel le boîtier est construit en verre.

36. Procédé selon l'une quelconque des revendications 1 à 15 ou 30 à 35, ou dispositif selon l'une quelconque des revendications 15 à 35, dans lequel l'interféron β est de l'interféron β-1a.


TUNGSTEN CONCENTRATION (ppb)
10000.000
9000.000
8000.000
7000.000
6000.000
5000.000
4000.000
3000.000
2000.000
1000.000
0.000
y = 131.194 + 179.32
R2 = .09893
y = 0.0838x + 2.2514
R2 = 0.9725
◇ % AGGREGATE
□ W (ppb)
70.0
60.0
50.0
40.0
30.0
20.0
10.0
0.0
% AGGREGATION
0
100
200
300
400
500
600
700
TIME (HOURS)

FIG. 1



Figure 2



Figure 3



FIG. 4

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 6352522 B **[0033]**
- US 6263641 B **[0033]**
- US 4895716 A **[0033]**
- US 4266557 A **[0033]**
- WO 9828007 A **[0038]**

Non-patent literature cited in the description

- **HOUGHTON.** The Complete Amino Acid Sequence of Human Fibroblast Interferon as Deduced Using Synthetic Oligodeoxyribonucleotide Primers of Reverse Transcriptase. *Nucleic Acids Research,* 1980, vol. 8, 2885-94 **[0003]**
- **T. TANIGUCHI et al.** The Nucleotide Sequence of Human Fibroblast DNA. *Gene,* 1980, vol. 10, 11-15 **[0003]**

AZ INTERFERON-BÉTA SZÁLLÍTÁSÁRA SZOLGÁLÓ MÓDSZER

Igénypontok

1. Egy olyan eszköz készítésére szolgáló módszer, amely interferon-β oldat tárolására való burkolatot tartalmaz, ahol a módszer a következőket foglalja magában:
   (a) a burkolat tisztítása savas és bázisos mosással az aggregáló fém eltávolításához mennyiségének csökkentéséhez azon a felületen, amely használat során közvetlenül érintkezne az interferon-β oldattal;
   (b) az interferon-β oldat betöltése a burkolatba, ahol az oldat betöltése után a burkolat adott koncentrációjú aggregáló fémet bocsát ki az oldatba kevesebb, mint 500 ppb mennyiségben, miután az oldat körülbelül 10 percnél hosszabb ideig marad a burkolatban.

2. Egy olyan eszköz készítésére szolgáló módszer, amely interferon-β oldat tárolására való burkolatot tartalmaz, ahol a módszer a következőket foglalja magában:
   (a) a burkolat elkészítése olyan módon, hogy csökkenjen az aggregáló fém mennyisége azon a felületen, amely használat során közvetlenül érintkezne az interferon-β oldattal;
   (b) az interferon-β oldat betöltése a burkolatba, ahol az oldat betöltése után a burkolat adott koncentrációjú aggregáló fémet bocsát ki az oldatba kevesebb, mint 500 ppb mennyiségben, miután az oldat körülbelül 10 percnél hosszabb ideig marad a burkolatban.

3. Az 1. vagy 2. igénypont szerinti módszer, ahol a burkolat adott koncentrációjú aggregáló fémet bocsát ki kevesebb, mint 500 ppb mennyiségben, miután az oldat 120 percnél hosszabb ideig marad a burkolatban.

4. Az 1. vagy 2. igénypont szerinti módszer, ahol a burkolat adott koncentrációjú aggregáló fémet bocsát ki kevesebb, mint 500 ppb mennyiségben, miután az oldat 360 percnél hosszabb ideig marad a burkolatban.

5. Az 1. vagy 2. igénypont szerinti módszer, ahol a burkolat adott koncentrációjú aggregáló fémet bocsát ki kevesebb, mint 500 ppb mennyiségben, miután az oldat 480 percnél hosszabb ideig marad a burkolatban.

6. Az 1. vagy 2. igénypont szerinti módszer, ahol a burkolat adott koncentrációjú aggregáló fémet bocsát ki kevesebb, mint 500 ppb mennyiségben, miután az oldat körülbelül 120–480 percig marad a burkolatban.

7. Az 1. vagy 2. igénypont szerinti módszer, ahol a burkolat adott koncentrációjú aggregáló fémet bocsát ki kevesebb, mint 500 ppb mennyiségben, miután az oldat körülbelül 300–420 percig marad a burkolatban.

8. Az 1. vagy 2. igénypont szerinti módszer, ahol a burkolat adott koncentrációjú aggregáló fémet bocsát ki kevesebb, mint 250 ppb mennyiségben.

9. Az 1. vagy 2. igénypont szerinti módszer, ahol a burkolat adott koncentrációjú aggregáló fémet bocsát ki kevesebb, mint 100 ppb mennyiségben.

10. Az 1. vagy 2. igénypont szerinti módszer, ahol a burkolat adott koncentrációjú aggregáló fémet bocsát ki kevesebb, mint 75 ppb mennyiségben.

11. Az 1. vagy 2. igénypont szerinti módszer, ahol a burkolat adott koncentrációjú aggregáló fémet bocsát ki kevesebb, mint 50 ppb mennyiségben.

12. Az 1. vagy 2. igénypont szerinti módszer, ahol az oldatban az aggregáló fém által okozott interferon-β aggregálódása kevesebb, mint 15% tárolás után.

13. Az 1. vagy 2. igénypont szerinti módszer, ahol az oldatban az aggregáló fém által okozott interferon-β aggregálódása kevesebb, mint 10% tárolás után.

14. Az 1. vagy 2. igénypont szerinti módszer, ahol az oldatban az aggregáló fém által okozott interferon-β aggregálódása kevesebb, mint 5% tárolás után.

15. Az 1. vagy 2. igénypont szerinti módszer, ahol az oldatban az aggregáló fém által okozott interferon-β aggregálódása kevesebb, mint 2% tárolás után.

16. Egy eszköz, amely a következőket tartalmazza:
(a) egy interferon-β oldat tárolására való burkolat;
(b) a burkolatban tárolt interferon-β oldat,
ahol a burkolat adott koncentrációjú aggregáló fémet bocsát ki az interferon-β oldatba kevesebb, mint 500 ppb mennyiségben, miután az oldat körülbelül 10 percnél hosszabb ideig marad a burkolatban.

17. A 16. igénypont szerinti módszer, ahol a burkolat adott összkoncentrációjú aggregáló fémet bocsát ki kevesebb, mint 250 ppb mennyiségben.

18. A 16. igénypont szerinti módszer, ahol a burkolat adott összkoncentrációjú aggregáló fémet bocsát ki kevesebb, mint 100 ppb mennyiségben.

19. A 16. igénypont szerinti módszer, ahol a burkolat adott összkoncentrációjú aggregáló fémet bocsát ki kevesebb, mint 75 ppb mennyiségben.

20. A 16. igénypont szerinti módszer, ahol a burkolat adott összkoncentrációjú aggregáló fémet bocsát ki kevesebb, mint 50 ppb mennyiségben.

21. A 16. igénypont szerinti módszer, ahol a burkolat adott összkoncentrációjú aggregáló fémet bocsát ki kevesebb, mint 500 ppb mennyiségben, miután az oldat 120 percnél hosszabb ideig marad a burkolatban.

22. A 16. igénypont szerinti módszer, ahol a burkolat adott összkoncentrációjú aggregáló fémet bocsát ki kevesebb, mint 500 ppb mennyiségben, miután az oldat 360 percnél hosszabb ideig marad a burkolatban.

23. A 16. igénypont szerinti módszer, ahol a burkolat adott összkoncentrációjú aggregáló fémet bocsát ki kevesebb, mint 500 ppb mennyiségben, miután az oldat 480 percnél hosszabb ideig marad a burkolatban.

24. A 16. igénypont szerinti módszer, ahol a burkolat adott összkoncentrációjú aggregáló fémet bocsát ki kevesebb, mint 500 ppb mennyiségben, miután az oldat körülbelül 120–480 percig marad a burkolatban.

25. A 16. igénypont szerinti módszer, ahol a burkolat adott összkoncentrációjú aggregáló fémet bocsát ki kevesebb, mint 500 ppb mennyiségben, miután az oldat körülbelül 300–420 percig marad a burkolatban.

26. Az 16. igénypont szerinti módszer, ahol az aggregáló fém által okozott interferon-β aggregálódása kevesebb, mint 15% tárolás után.

27. Az 16. igénypont szerinti módszer, ahol az aggregáló fém által okozott interferon-β aggregálódása kevesebb, mint 10% tárolás után.

28. Az 16. igénypont szerinti módszer, ahol az aggregáló fém által okozott interferon-β aggregálódása kevesebb, mint 5% tárolás után.

29. Az 16. igénypont szerinti módszer, ahol az aggregáló fém által okozott interferon-β aggregálódása kevesebb, mint 2% tárolás után.

30. Az 1–15. igénypontok bármelyike szerinti módszer vagy a 16–29. igénypontok bármelyike szerinti eszköz, ahol az aggregáló fémet a következőket tartalmazó csoportból választják ki: vas, réz, nikkel, molibdén és volfrám.

31. A 30. igénypont szerinti módszer vagy eszköz, ahol az aggregáló fém volfrám.

32. Az 1–15. igénypontok bármelyike szerinti módszer vagy a 16–29. igénypontok bármelyike szerinti eszköz, ahol az eszköz fecskendő, palack, fiola vagy tasak.

33. A 32. igénypont szerinti módszer vagy eszköz, ahol az eszköz fecskendő.

34. Az 1–15. igénypontok bármelyike szerinti módszer vagy a 16–29. igénypontok bármelyike szerinti eszköz, ahol az eszköz anyaga üveg, fém vagy műanyag.

35. A 34. igénypont szerinti módszer, ahol a burkolat üvegből készült.

36. Az 1–15. és 30–35. igénypontok bármelyike szerinti módszer vagy a 15–35. igénypontok bármelyike szerinti eszköz, ahol az interferon-β interferon-β-1 a.